• Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. (nih.gov)
  • To investigate mechanisms of cartilage matrix destruction by a study of the effects of a specific inactivator of cathepsin B and an inhibitor of several matrix metalloproteinases (MMP) on cartilage proteoglycan release. (nih.gov)
  • Cathepsin B is implicated in rHuIL-1 alpha-stimulated loss of cartilage proteoglycan. (nih.gov)
  • Its lack of involvement in retinoic acid-stimulated proteoglycan release suggests the existence of at least 2 pathways of cartilage proteoglycan breakdown, which may converge at the activation of a matrix prometalloproteinase. (nih.gov)
  • This graph shows the total number of publications written about "Aggrecans" by people in this website by year, and whether "Aggrecans" was a major or minor topic of these publications. (umassmed.edu)
  • Cartilage explants were treated with either recombinant human interleukin-1 alpha (rHuIL-1 alpha) or retinoic acid in the presence or absence of the inhibitors, and proteoglycan release was quantitated. (nih.gov)
  • Markaryan A, Nelson EG, Kohut RI, Hinojosa R. Dual immunofluorescence staining of proteoglycans in human temporal bones. (uchicago.edu)
  • Bone mesenchymal stem cells transplanted into rabbit intervertebral discs can increase proteoglycans. (nih.gov)
  • We sought to determine whether transplanted allogeneic bone mesenchymal stem cells can survive and increase the amount of proteoglycans in intervertebral discs. (nih.gov)
  • Our data suggest transplanted allogenic bone mesenchymal stem cells can survive and increase proteoglycan amount, supporting its potential use as a treatment of intervertebral disc degeneration. (nih.gov)